Bayer and Regeneron Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
- Details
- Category: Bayer
Bayer HealthCare and Regeneron Pharmaceuticals, Inc. have initiated the first of two Phase 3 clinical trials evaluating the efficacy and safety of VEGF Trap-Eye (aflibercept ophthalmic solution), an investigational new agent for the treatment of certain eye diseases, in the treatment of Diabetic Macular Edema (DME).
Amgen Establishes Commercial Operations in Brazil
- Details
- Category: Amgen
Amgen (NASDAQ: AMGN), the world's largest biotechnology company, announced the expansion of its operations in Brazil, including the acquisition of Bergamo, a privately-held Brazilian pharmaceutical company.
Novartis sells global rights to Elidel®, a medicine to treat atopic dermatitis
- Details
- Category: Novartis
Novartis has signed an agreement to sell to Meda the global rights to manufacture, market and commercialize Elidel® (pimecrolimus) Cream 1%, a medicine to treat mild to moderate atopic dermatitis.
FDA approves orphan drug vandetanib
- Details
- Category: AstraZeneca
AstraZeneca today announced that the US Food and Drug Administration (FDA) approved the orphan drug vandetanib for the treatment of medullary thyroid cancer that cannot be removed by surgery or that has spread to other parts of the body.
Sanofi-aventis Successfully Completes Exchange Offer for Genzyme Corporation
- Details
- Category: Sanofi
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) has successfully completed its exchange offer for all outstanding shares of common stock of Genzyme Corporation (NASDAQ: GENZ).
Pfizer to Sell Capsugel to KKR
- Details
- Category: Pfizer
Pfizer and Kohlberg Kravis Roberts & Co L.P. (together with its affiliates, "KKR") have entered into an agreement whereby an affiliate of KKR will acquire Pfizer's Capsugel business for $2.375 billion in cash.
Boehringer Ingelheim's lead hepatitis C compound moves into phase III
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim announced the study outline for the pivotal Phase III clinical trials designed to evaluate BI 201335, its investigational once-daily oral protease inhibitor, in both treatment-naïve and -experienced patients with chronic genotype-1 hepatitis C virus (HCV), the most challenging genotype to treat.
More Pharma News ...
- GSK publishes payments for research, consulting and advising by US healthcare professionals
- Pfizer Posts Details Of Interactions With U.S. Health Care Professionals And Researchers In 2010
- REACT study to evaluate impact of Daxas® (roflumilast) in patients receiving standard COPD treatment
- Sanofi-aventis Announces Registration Statement for CVR Related to Genzyme Acquisition Declared Effective
- A new pharmaceutical candidate enters Lundbeck's development pipeline
- Merck and Its Employees to Donate to Japanese Relief Effort
- UK and US governments reach agreement over AstraZeneca tax matters